# Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

> **NCT06483100** · PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 65 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elrantamab
- **DEVICE:** clonoSEQ

## Key facts

- **NCT ID:** NCT06483100
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483100, "Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06483100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*